Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics to Develop miRNA Markers for Henry Ford's Brain Cancer Team

NEW YORK (GenomeWeb News) – Rosetta Genomics will develop microRNA-based diagnostics and prognostics for brain cancer with the Henry Ford Hospital, the company said today.
 
The company will work with researchers at the William and Karen Davidson Laboratory of Cell Signaling & Tumorigenes to conduct genome-wide association studies in search of miRNA biomarkers with predictive and diagnostic potential. Rosetta Genomics will use the results of those studies to perform miRNA analysis of formalin-fixed paraffin-embedded samples from the Henry Ford Hospital.
 
The Detroit-based hospital plans to use any diagnostic or prognostic biomarkers found in the research to manage disease staging and to predict patient response to treatment and the risk of recurrence of the disease.